Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.54 |
| ▸ | NQO2 | P16083 | 4/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890342 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AAKR1C3NQO2 | |
| SCHEMBL3793596 | 0.88 | PPARG (0.59) | ALDH1A1MEN1KMT2AAKR1C3NQO2 | |
| SCHEMBL3797579 | 0.88 | PPARG (0.59) | ALDH1A1MEN1KMT2AAKR1C3NQO2 | |
| SCHEMBL3793593 | 0.88 | PPARG (0.59) | ALDH1A1MEN1KMT2AAKR1C3NQO2 | |
| SCHEMBL27838696 | 0.87 | MEN1 (0.64) | ALDH1A1MEN1KMT2AAKR1C3NQO2 | |
| SCHEMBL3797950 | 0.85 | PARP10 (0.50) | ALDH1A1MEN1KMT2AAKR1C3PARP10 | |
| SCHEMBL3797946 | 0.85 | PARP10 (0.50) | ALDH1A1MEN1KMT2AAKR1C3PARP10 | |
| SCHEMBL14087896 | 0.85 | MEN1 (0.53) | ALDH1A1MEN1KMT2AAKR1C3NQO2 | |
| SCHEMBL14087904 | 0.84 | AKR1C3 (0.75) | AKR1C3 | |
| SCHEMBL14087892 | 0.84 | MTNR1A (0.59) | ALDH1A1MEN1KMT2AAKR1C3NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112209896-B | Thiazolidinedione derivatives and pharmaceutical compositions containing the same | 苏州泽璟生物制药股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-112209896-A | Thiazolidinedione derivatives and pharmaceutical compositions containing the same | 苏州泽璟生物制药股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080108825-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108825-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108825-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7323496-B2 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323496-B2 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323496-B2 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | NEOGI PARTHA | 2007-11-08 | — | — | US | disclosed |
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | NEOGI PARTHA | 2007-11-08 | — | — | US | disclosed |
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | NEOGI PARTHA | 2007-11-08 | — | — | US | disclosed |
| US-20040097593-A1 | Compounds for treatment of inflammation, diabetes and related disorders | SEED, BRIAN | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | CPS1, ABAT, IL6 | ALDH1A1 2718/4885MEN1 3284/4885KMT2A 1903/4885 |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | ALDH1A1 2681/4885MEN1 3293/4885KMT2A 1862/4885 |
| US-20080108825-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | ALDH1A1 2681/4885MEN1 3293/4885KMT2A 1862/4885 |
| US-20040097593-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | ALDH1A1 2718/4885MEN1 3284/4885KMT2A 1903/4885 |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | ALDH1A1 2681/4885MEN1 3293/4885KMT2A 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.